|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giovannucci E, Liu Y, Platz EA, Stampfer
MJ and Willett WC: Risk factors for prostate cancer incidence and
progression in the health professionals follow-up study. Int J
Cancer. 121:1571–1578. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chandrasekar T, Yang JC, Gao AC and Evans
CP: Mechanisms of resistance in castration-resistant prostate
cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI
|
|
5
|
Batista RL and Mendonca BB: Integrative
and analytical review of the 5-alpha-reductase type 2 deficiency
worldwide. Appl Clin Genet. 13:83–96. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kokal M, Mirzakhani K, Pungsrinont T and
Baniahmad A: Mechanisms of androgen receptor agonist- and
antagonist-mediated cellular senescence in prostate cancer. Cancers
(Basel). 12:18332020. View Article : Google Scholar
|
|
7
|
Kregel S, Bagamasbad P, He S, LaPensee E,
Raji Y, Brogley M, Chinnaiyan A, Cieslik M and Robins DM:
Differential modulation of the androgen receptor for prostate
cancer therapy depends on the DNA response element. Nucleic Acids
Res. 48:4741–4755. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ross RK, Bernstein L, Lobo RA, Shimizu H,
Stanczyk FZ, Pike MC and Henderson BE: 5-alpha-reductase activity
and risk of prostate cancer among Japanese and US white and black
males. Lancet. 339:887–889. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Makridakis N, Ross RK, Pike MC, Chang L,
Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE and Reichardt
JK: A prevalent missense substitution that modulates activity of
prostatic steroid 5alpha-reductase. Cancer Res. 57:1020–1022.
1997.PubMed/NCBI
|
|
10
|
Ntais C, Polycarpou A and Ioannidis JP:
SRD5A2 gene polymorphisms and the risk of prostate cancer: A
meta-analysis. Cancer Epidemiol Biomarkers Prev. 12:618–624.
2003.PubMed/NCBI
|
|
11
|
Reichardt JK, Makridakis N, Henderson BE,
Yu MC, Pike MC and Ross RK: Genetic variability of the human SRD5A2
gene: Implications for prostate cancer risk. Cancer Res.
55:3973–3975. 1995.PubMed/NCBI
|
|
12
|
Davis DL and Russell DW: Unusual length
polymorphism in human steroid 5 alpha-reductase type 2 gene
(SRD5A2). Hum Mol Genet. 2:8201993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ruijter E, van de Kaa C, Miller G, Ruiter
D, Debruyne F and Schalken J: Molecular genetics and epidemiology
of prostate carcinoma. Endocr Rev. 20:22–45. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Makridakis NM, di Salle E and Reichardt
JK: Biochemical and pharmacogenetic dissection of human steroid 5
alpha-reductase type II. Pharmacogenetics. 10:407–413. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hsing AW, Chen C, Chokkalingam AP, Gao YT,
Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK,
et al: Polymorphic markers in the SRD5A2 gene and prostate cancer
risk: A population-based case-control study. Cancer Epidemiol
Biomarkers Prev. 10:1077–1082. 2001.PubMed/NCBI
|
|
16
|
Makridakis NM, Ross RK, Pike MC, Crocitto
LE, Kolonel LN, Pearce CL, Henderson BE and Reichardt JK:
Association of mis-sense substitution in SRD5A2 gene with prostate
cancer in African-American and Hispanic men in Los Angeles, USA.
Lancet. 354:975–978. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Neslund-Dudas C, Bock CH, Monaghan K, Nock
NL, Yang JJ, Rundle A, Tang D and Rybicki BA: SRD5A2 and HSD3B2
polymorphisms are associated with prostate cancer risk and
aggressiveness. Prostate. 67:1654–1663. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Russell DW and Wilson JD: Steroid 5
alpha-reductase: Two genes/two enzymes. Annu Rev Biochem. 63:25–61.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Huang Y, Fu X, Chen C, Zhang D, Yan
L, Xie Y, Mao Y and Li Y: Meta-analysis of three polymorphisms in
the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2)
and risk of prostate cancer. Mutagenesis. 26:371–383. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bentley AR, Callier S and Rotimi CN:
Diversity and inclusion in genomic research: Why the uneven
progress? J Community Genet. 8:255–266. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moreno-Estrada A, Gignoux CR,
Fernández-López JC, Zakharia F, Sikora M, Contreras AV,
Acuña-Alonzo V, Sandoval K, Eng C, Romero-Hidalgo S, et al: Human
genetics. The genetics of Mexico recapitulates Native American
substructure and affects biomedical traits. Science. 344:1280–1285.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Silva-Zolezzi I, Hidalgo-Miranda A,
Estrada-Gil J, Fernandez-Lopez JC, Uribe-Figueroa L, Contreras A,
Balam-Ortiz E, del Bosque-Plata L, Velazquez-Fernandez D, Lara C,
et al: Analysis of genomic diversity in Mexican Mestizo populations
to develop genomic medicine in Mexico. Proc Natl Acad Sci USA.
106:8611–8616. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Villarreal-Martínez A, Gallardo-Blanco H,
Cerda-Flores R, Torres-Muñoz I, Gómez-Flores M, Salas-Alanís J,
Ocampo-Candiani J and Martínez-Garza L: Candidate gene
polymorphisms and risk of psoriasis: A pilot study. Exp Ther Med.
11:1217–1222. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Patiño-García B, Arroyo C,
Rangel-Villalobos H, Soto-Vega E, Velarde-Félix JS, Gabilondo F,
Sandoval-Ramirez L and Figuera LE: Association between
polymorphisms of the androgen and vitamin D receptor genes with
prostate cancer risk in a Mexican population. Rev Invest Clin.
59:25–31. 2007.PubMed/NCBI
|
|
25
|
Martinez-Fierro ML, Garza-Veloz I,
Rojas-Martinez A, Ortiz-Lopez R, Castruita-de la Rosa C,
Ortiz-Castro Y, Lazalde- Ramos BP, Cervantes-Villagrana AR,
Castañeda-Lopez ME, Gomez-Guerra L, et al: Positive association
between vascular endothelial growth factor (VEGF) −2578 C/A variant
and prostate cancer. Cancer Biomark. 13:235–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Canto P, Benítez Granados J, Martínez
Ramírez MA, Reyes E, Feria-Bernal G, García-García E, Tejeda ME,
Zavala E, Tapia A, Rojano-Mejía D and Méndez JP: Genetic variants
in ATP6 and ND3 mitochondrial genes are not associated with
aggressive prostate cancer in Mexican-Mestizo men with overweight
or obesity. Aging Male. 19:187–191. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sanchez-Dominguez CN, Reyes-Lopez MA,
Bustamante A, Cerda-Flores RM, Villalobos-Torres Mdel C, Gallardo-
Blanco HL, Rojas-Martinez A, Martinez-Rodriguez HG, Barrera-Saldaña
HA and Ortiz-Lopez R: The tumor necrosis factor alpha (−308 A/G)
polymorphism is associated with cystic fibrosis in Mexican
patients. PLoS One. 9:e909452014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jaramillo-Rangel G, Ortega-Martínez M,
Cerda-Flores RM and Barrera-Saldaña HA: C3435T polymorphism in the
MDR1 gene and breast cancer risk in northeastern Mexico. Int J Clin
Exp Pathol. 11:904–909. 2018.PubMed/NCBI
|
|
29
|
Zhao F, Song M, Wang Y and Wang W: Genetic
model. J Cell Mol Med. 20:7652016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Srigley JR, Delahunt B, Samaratunga H,
Billis A, Cheng L, Clouston D, Evans A, Furusato B, Kench J, Leite
K, et al: Controversial issues in Gleason and International Society
of Urological Pathology (ISUP) prostate cancer grading: Proposed
recommendations for international implementation. Pathology.
51:463–473. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Canto P, Vilchis F, Chávez B, Mutchinick
O, Imperato-McGinley J, Pérez-Palacios G, Ulloa-Aguirre A and
Méndez JP: Mutations of the 5 alpha-reductase type 2 gene in eight
Mexican patients from six different pedigrees with 5
alpha-reductase-2 deficiency. Clin Endocrinol (Oxf). 46:155–160.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chávez B, Valdez E and Vilchis F:
Uniparental disomy in steroid 5alpha-reductase 2 deficiency. J Clin
Endocrinol Metab. 85:3147–3150. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vilchis F, Valdez E, Ramos L, García R,
Gómez R and Chávez B: Novel compound heterozygous mutations in the
SRD5A2 gene from 46, XY infants with ambiguous external genitalia.
J Hum Genet. 53:401–406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shih EM and Graham JM Jr: Review of
genetic and environmental factors leading to hypospadias. Eur J Med
Genet. 57:453–463. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou ZR, Wang WW, Li Y, Jin KR, Wang XY,
Wang ZW, Chen YS, Wang SJ, Hu J, Zhang HN, et al: In-depth mining
of clinical data: The construction of clinical prediction model
with R. Ann Transl Med. 7:632019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dong R, Jiang J, Zhang S, Shen Z, Chen G,
Huang Y, Zheng Y and Zheng S: Development and validation of novel
diagnostic models for biliary atresia in a large cohort of Chinese
patients. EBioMedicine. 34:223–230. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun G, Nakayama Y, Dagdanpurev S, Abe S,
Nishimura H, Kirimoto T and Matsui T: Remote sensing of multiple
vital signs using a CMOS camera-equipped infrared thermography
system and its clinical application in rapidly screening patients
with suspected infectious diseases. Int J Infect Dis. 55:113–117.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shiota M, Fujimoto N, Yokomizo A, Takeuchi
A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K and
Eto M: The prognostic impact of serum testosterone during androgen-
deprivation therapy in patients with metastatic prostate cancer and
the SRD5A2 polymorphism. Prostate Cancer Prostatic Dis. 19:191–196.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kusuma Duarsa GW, Sari YA, Gde Oka AA,
Santosa KB, Yudiana IW, Wisnu Tirtayasa PM, Putra Pramana IB and
Kloping YP: Serum testosterone and prostate-specific antigen levels
are major risk factors for prostatic volume increase among benign
prostatic hyperplasia patients. Asian J Urol. Jun 7–2020.(Epub
ahead of print). doi: org/10.1016/j.ajur.2020.06.001. View Article : Google Scholar
|
|
40
|
Golchin-Rad K, Mogheiseh A, Nazifi S,
Ahrari Khafi MS, Derakhshandeh N and Abbaszadeh-Hasiri M: Changes
in the serum prostatic biomarkers during the treatment of benign
prostatic hyperplasia with a 5alpha-REDUCTASE inhibitor:
Finasteride. Top Companion Anim Med. 38:1004052020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gomez-Guerra LS, Martinez-Fierro ML,
Alcantara-Aragon V, Ortiz-Lopez R, Martinez-Villarreal RT,
Morales-Rodriguez IB, Garza-Guajardo R, Ponce-Camacho MA and
Rojas-Martinez A: Population based prostate cancer screening in
north Mexico reveals a high prevalence of aggressive tumors in
detected cases. BMC Cancer. 9:912009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee J, Giovannucci E and Jeon JY: Diabetes
and mortality in patients with prostate cancer: A meta-analysis.
Springerplus. 5:15482016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Marrone MT, Selvin E, Barber JR, Platz EA
and Joshu CE: Hyperglycemia, classified with multiple biomarkers
simultaneously in men without diabetes, and risk of fatal prostate
cancer. Cancer Prev Res (Phila). 12:103–112. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bansal D, Bhansali A, Kapil G, Undela K
and Tiwari P: Type 2 diabetes and risk of prostate cancer: A
meta-analysis of observational studies. Prostate Cancer Prostatic
Dis. 16:151–158, S1. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin E, Garmo H, Van Hemelrijck M,
Adolfsson J, Stattin P, Zethelius B and Crawley D: Association of
type 2 diabetes mellitus and antidiabetic medication with risk of
prostate cancer: A population-based case-control study. BMC Cancer.
20:5512020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tseng CH: Metformin significantly reduces
incident prostate cancer risk in Taiwanese men with type 2 diabetes
mellitus. Eur J Cancer. 50:2831–2837. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Azoulay L, Dell'Aniello S, Gagnon B,
Pollak M and Suissa S: Metformin and the incidence of prostate
cancer in patients with type 2 diabetes. Cancer Epidemiol
Biomarkers Prev. 20:337–344. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Häggström C, Van Hemelrijck M, Zethelius
B, Robinson D, Grundmark B, Holmberg L, Gudbjörnsdottir S, Garmo H
and Stattin P: Prospective study of Type 2 diabetes mellitus,
anti-diabetic drugs and risk of prostate cancer. International
journal of cancer Journal international du cancer. 140:611–617.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Garza-Guajardo R, Delgado-Enciso I,
Melo-De-La-Garza A, Rodriguez-Sanchez I, Laura GL, Martinez-Fierro
ML, Gómez-Guerra L, Gómez-Macías GS, Barboza-Quintana A,
Guzmán-Esquivel J, et al: High fasting glucose, but not metabolic
syndrome, is associated with elevated histologic aggressiveness in
Mexican prostate cancer patients. Int J Clin Exp Pathol.
9:11951–11957. 2016.
|
|
50
|
Plaskon LA, Penson DF, Vaughan TL and
Stanford JL: Cigarette smoking and risk of prostate cancer in
middle-aged men. Cancer Epidemiol Biomarkers Prev. 12:604–609.
2003.PubMed/NCBI
|
|
51
|
Zu K and Giovannucci E: Smoking and
aggressive prostate cancer: A review of the epidemiologic evidence.
Cancer Causes Control. 20:1799–1810. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huncharek M, Haddock KS, Reid R and
Kupelnick B: Smoking as a risk factor for prostate cancer: A
meta-analysis of 24 prospective cohort studies. Am J Public Health.
100:693–701. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
How Tobacco Smoke Causes Disease, . The
Biology and Behavioral Basis for Smoking-Attributable Disease. A
Report of the Surgeon General. Centers for Disease Control and
Prevention; Atlanta, GA: 2010
|
|
54
|
Xue J, Yang S and Seng S: Mechanisms of
cancer induction by tobacco-specific NNK and NNN. Cancers (Basel).
6:1138–1156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Baird WM, Hooven LA and Mahadevan B:
Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and
mechanism of action. Environ Mol Mutagen. 45:106–114. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zelikoff JT, Chen LC, Cohen MD and
Schlesinger RB: The toxicology of inhaled woodsmoke. J Toxicol
Environ Health B Crit Rev. 5:269–282. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
IARC Working Group on the Evaluation of
Carcinogenic Risk to Humans. Household Use of Solid Fuels and
High-temperature Frying. Lyon (FR): International Agency for
Research on Cancer; 2010, (IARC Monographs on the Evaluation of
Carcinogenic Risks to Humans, No. 95.) 2, Studies of Cancer in
Humans. https://www.ncbi.nlm.nih.gov/books/NBK385519/
|
|
58
|
Li N, Luo HD, Jia YZ, Zhou N and Li YQ:
Rapid determination of benzo(a)pyrene in processed meat and fish
samples by second-derivative constant-energy synchronous
fluorescence spectrometry. Food Addit Contam Part A Chem Anal
Control Expo Risk Assess. 28:235–242. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bouaoun L, Sonkin D, Ardin M, Hollstein M,
Byrnes G, Zavadil J and Olivier M: TP53 Variations in human
cancers: New lessons from the IARC TP53 database and genomics data.
Hum Mutat. 37:865–876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Stellman SD, Demers PA, Colin D and
Boffetta P: Cancer mortality and wood dust exposure among
participants in the American Cancer Society Cancer Prevention
Study-II (CPS-II). Am J Ind Med. 34:229–237. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chen B, Cole JW and Grond-Ginsbach C:
Departure from Hardy Weinberg Equilibrium and genotyping error.
Front Genet. 8:1672017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
McQuillan R, Leutenegger AL, Abdel-Rahman
R, Franklin CS, Pericic M, Barac-Lauc L, Smolej-Narancic N,
Janicijevic B, Polasek O, Tenesa A, et al: Runs of homozygosity in
European populations. Am J Hum Genet. 83:359–372. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Paz-y-Miño C, Witte T, Robles P,
Llumipanta W, Diaz M and Arevalo M: Association among polymorphisms
in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate
cancer risk, and pathologic characteristics of prostate tumors in
an Ecuadorian population. Cancer Genet Cytogenet. 189:71–76. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fang C, Guo ZQ, Chen XY, Liu TZ, Zeng XT
and Wang XH: Relationship between SRD5A2 rs9282858 polymorphism and
the susceptibility of prostate cancer: A meta-analysis based on 20
publications. Medicine (Baltimore). 96:e67912017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ribeiro ML, Santos A, Carvalho-Salles AB
and Hackel C: Allelic frequencies of six polymorphic markers for
risk of prostate cancer. Braz J Med Biol Res. 35:205–213. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Pearce CL, Van Den Berg DJ, Makridakis N,
Reichardt JK, Ross RK, Pike MC, Kolonel LN and Henderson BE: No
association between the SRD5A2 gene A49T missense variant and
prostate cancer risk: Lessons learned. Hum Mol Genet. 17:2456–2461.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Mateo J, Carreira S, Sandhu S, Miranda S,
Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A,
Tunariu N, et al: DNA-Repair Defects and Olaparib in Metastatic
Prostate Cancer. N Engl J Med. 373:1697–1708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ruscetti MA and Wu H: PTEN in prostate
cancer. Prostate Cancer. 87–137. 2013. View Article : Google Scholar
|
|
69
|
Ecke TH, Schlechte HH, Schiemenz K, Sachs
MD, Lenk SV, Rudolph BD and Loening SA: TP53 gene mutations in
prostate cancer progression. Anticancer Res. 30:1579–1586.
2010.PubMed/NCBI
|
|
70
|
Loukola A, Chadha M, Penn SG, Rank D,
Conti DV, Thompson D, Cicek M, Love B, Bivolarevic V, Yang Q, et
al: Comprehensive evaluation of the association between prostate
cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur
J Hum Genet. 12:321–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Salam MT, Ursin G, Skinner EC, Dessissa T
and Reichardt JK: Associations between polymorphisms in the steroid
5-alpha reductase type II (SRD5A2) gene and benign prostatic
hyperplasia and prostate cancer. Urol Oncol. 23:246–253. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Cussenot O, Azzouzi AR, Nicolaiew N,
Mangin P, Cormier L, Fournier G, Valeri A and Cancel-Tassin G:
Low-activity V89L variant in SRD5A2 is associated with aggressive
prostate cancer risk: An explanation for the adverse effects
observed in chemoprevention trials using 5-alpha-reductase
inhibitors. Eur Urol. 52:1082–1087. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Sӧderstrӧm T, Wadelius M, Andersson SO,
Johansson JE, Johansson S, Granath F and Rane A: 5alpha-reductase 2
polymorphisms as risk factors in prostate cancer. Pharmacogenetics.
12:307–312. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
LaTulippe E, Satagopan J, Smith A, Scher
H, Scardino P, Reuter V and Gerald WL: Comprehensive gene
expression analysis of prostate cancer reveals distinct
transcriptional programs associated with metastatic disease. Cancer
Res. 62:4499–4506. 2002.PubMed/NCBI
|
|
75
|
Chandran UR, Ma C, Dhir R, Bisceglia M,
Lyons-Weiler M, Liang W, Michalopoulos G, Becich M and Monzon FA:
Gene expression profiles of prostate cancer reveal involvement of
multiple molecular pathways in the metastatic process. BMC Cancer.
7:642007. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Stanbrough M, Bubley GJ, Ross K, Golub TR,
Rubin MA, Penning TM, Febbo PG and Balk SP: Increased expression of
genes converting adrenal androgens to testosterone in
androgen-independent prostate cancer. Cancer Res. 66:2815–2825.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Obinata D, Takayama K, Takahashi S and
Inoue S: Crosstalk of the androgen receptor with transcriptional
collaborators: Potential therapeutic targets for
castration-resistant prostate cancer. Cancers (Basel). 9:222017.
View Article : Google Scholar
|
|
78
|
Squire JA: TMPRSS2-ERG and PTEN loss in
prostate cancer. Nat Genet. 41:509–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kiflemariam S, Mignardi M, Ali MA, Bergh
A, Nilsson M and Sjoblom T: In situ sequencing identifies
TMPRSS2-ERG fusion transcripts, somatic point mutations and gene
expression levels in prostate cancers. J Pathol. 234:253–261.
2014.PubMed/NCBI
|
|
80
|
Li H, Wang Z, Tang K, Zhou H, Liu H, Yan
L, Guan W, Chen K, Xu H and Ye Z: Prognostic value of androgen
receptor splice variant 7 in the treatment of castration-resistant
prostate cancer with next generation androgen receptor signal
inhibition: A systematic review and meta-analysis. Eur Urol Focus.
4:529–539. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Markowski MC, Silberstein JL, Eshleman JR,
Eisenberger MA, Luo J and Antonarakis ES: Clinical utility of
CLIA-Grade AR-V7 testing in patients with metastatic
castration-resistant prostate cancer. JCO Precis Oncol. Oct
10–2017.(Epub ahead of print). doi: 10.1200/PO.17.00127, 2017.
View Article : Google Scholar
|
|
82
|
Szklarczyk D, Santos A, von Mering C,
Jensen LJ, Bork P and Kuhn M: STITCH 5: Augmenting protein-chemical
interaction networks with tissue and affinity data. Nucleic Acids
Res. 44:D380–D384. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Shiota M, Fujimoto N, Yokomizo A, Takeuchi
A, Itsumi M, Inokuchi J, Tatsugami K, Uchiumi T and Naito S: SRD5A
gene polymorphism in Japanese men predicts prognosis of metastatic
prostate cancer with androgen-deprivation therapy. Eur J Cancer.
51:1962–1969. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Torkko KC, van Bokhoven A, Mai P, Beuten
J, Balic I, Byers TE, Hokanson JE, Norris JM, Barón AE, Lucia MS,
et al: VDR and SRD5A2 polymorphisms combine to increase risk for
prostate cancer in both non-Hispanic White and Hispanic White men.
Clin Cancer Res. 14:3223–3229. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Zeng XT, Su XJ, Li S, Weng H, Liu TZ and
Wang XH: Association between SRD5A2 rs523349 and rs9282858
polymorphisms and risk of benign prostatic hyperplasia: A
meta-analysis. Front Physiol. 8:6882017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Rył A, Rotter I, Grzywacz A, Małecka I,
Skonieczna-Żydecka K, Grzesiak K, Słojewski M, Szylińska A,
Sipak-Szmigiel O, Piasecka M, et al: Molecular analysis of the
SRD5A1 and SRD5A2 genes in patients with benign prostatic
hyperplasia with regard to metabolic parameters and selected
hormone levels. Int J Environ Res Public Health. 14:13182017.
View Article : Google Scholar
|
|
87
|
Gu X, Na R, Huang T, Wang L, Tao S, Tian
L, Chen Z, Jiao Y, Kang J, Zheng S, et al: SRD5A1 and SRD5A2 are
associated with treatment for benign prostatic hyperplasia with the
combination of 5α-reductase inhibitors and α-adrenergic receptor
antagonists. J Urol. 190:615–619. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Choubey VK, Sankhwar SN, Carlus SJ, Singh
AN, Dalela D, Thangaraj K and Rajender S: SRD5A2 gene polymorphisms
and the risk of benign prostatic hyperplasia but not prostate
cancer. Asian Pac J Cancer Prev. 16:1033–1036. 2015. View Article : Google Scholar : PubMed/NCBI
|
